Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status.<h4>Results</h4>In total, 103 participants were randomized (May 2016-February 2019): 52 to CyA and 51 to MTX. This evidence concerns the gene FLG and Eczematoid dermatitis.